Lineage Cell Therapeutics, Inc.
LCTX
$0.4817
-$0.0183-3.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -7.88% | 47.33% | 11.95% | -37.01% | 32.84% |
| Total Depreciation and Amortization | 7.09% | -0.70% | -18.86% | 0.00% | -0.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -125.31% | -47.23% | 2.45% | 888.02% | -109.43% |
| Change in Net Operating Assets | 18.72% | -235.02% | -19.27% | 24.29% | -782.73% |
| Cash from Operations | -9.66% | -11.80% | 10.50% | 3.92% | -19.50% |
| Capital Expenditure | -225.89% | -124.00% | -31.58% | 58.24% | 34.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.00% | 145.75% | -- | -- | 334.90% |
| Cash from Investing | -32.23% | 144.22% | -23,039.47% | -100.39% | 359.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.69% | 7.14% | -7.69% | 0.00% | -8.33% |
| Issuance of Common Stock | 217,960.00% | -91.67% | -99.15% | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | 88.44% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 99.11% | -156.28% | 896.00% |
| Cash from Financing | 724,566.67% | -102.86% | -99.25% | 107,953.85% | -101.61% |
| Foreign Exchange rate Adjustments | -34.21% | 143.18% | -25.71% | -124.82% | 182.94% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,068.24% | 86.64% | -271.61% | 103.66% | 263.07% |
